Targets — browse / sort / filter (view)
Data license: CC BY 4.0 · Data source: apt-scout automated curation pipeline (E. Dohi, NCNP) — values harvested from public databases; raw source stored per target
- id
- UniProt accession (human). Links to uniprot.org.
- gene_symbol
- Gene symbol (e.g. ITGB3).
- protein_name
- Protein name (UniProt).
- tier
- Tier 1 = PDB-anchored; Tier 1.5 = AlphaFold-confident.
- has_structure
- 1 if the target protein has a reported experimental 3D structure (PDB). This is the CORE requirement the aptamer-Kd layer is built around — filter to 1 for the structure-backed set.
- evidence_priority
- DETERMINISTIC, reproducible prioritisation (0-1) computed at build time from real harvested columns: 0.35*experimental-structure(PDB=1 / AlphaFold-only=0.3) + 0.30*Open-Targets-top-disease-score + 0.20*PREDICTED-surface-accessibility(A_surface=1) + 0.15*EV-detection(EV-Map). A transparent ranking AID, not a validation; the surface/EV terms are PREDICTIONS/DETECTIONS, not measured EV-surface exposure. Recomputable exactly from this DB.
- has_activation_state_pdb_pair
- 1 if a curated ACTIVE/INACTIVE PDB pair exists (only 11 targets).
- in_cev_map
- Detected in the EV-Map plasma-EV dataset (Rai & Greening 2025, Nat Cell Biol, 10.1038/s41556-025-01795-7) = 3,422 apt-scout targets (broad detected proteome). The EV-Map CONSERVED EV proteome is 182 proteins (42 non-EV); apt-scout matches 104 of these conserved EV-hallmark proteins as targets by gene (the other 78 are not apt-scout targets). Use the ev_hallmark_targets query for that subset. IMPORTANT: EV-Map detection means the protein is EV CARGO (present in the vesicle) — it does NOT mean surface-exposed. Rai & Greening 2025 run a separate membrane-impermeant biotinylation assay giving a 151-protein SURFACEOME, and show the conserved SDCBP/syntenin is luminal (not surface-accessible). For genuine EV-surface accessibility use that 151-protein set, not EV-Map presence.
- has_known_aptamer
- 1 if PubMed '(gene) AND (aptamer OR SELEX)' returned any hit (KEYWORD co-mention, includes false positives — NOT a verified aptamer). For verified aptamers with Kd, see the Binding-affinities (v_kd) layer.
- opentargets_top_disease_score
- Open Targets association score (0-1).
- aptamer_count_pubmed
- Number of PubMed hits for (this protein) AND (aptamer OR SELEX). Keyword co-occurrence — verify each (many co-mention without a real aptamer).
- aptamer_pmids
- The actual PubMed IDs behind the aptamer evidence — click each to read the paper. This is the source of the 'has aptamer' claim.
- surface_class
- PREDICTED membrane topology (HPA-derived, not a measurement): A_surface = integral/ecto cell-surface (predicted EV-surface accessible); A2_pm_peripheral = plasma-membrane cytoplasmic-leaflet (SRC/LYN/RHOA, predicted not reachable); A_assoc = secreted/corona; B_cargo = luminal cargo; unknown = no HPA localization. Lipid asymmetry can partially flip (PS via scramblase); confirm by protease-protection / intact-EV surface labelling. See v_surface_targets.
132 rows where in_cev_map = 1, surface_class = "A2_pm_peripheral" and tier = "Tier 1.5" sorted by evidence_priority descending
This data as json, CSV (advanced)
Suggested facets: pdb_count_total, aptamer_count_pubmed
tier 1
- Tier 1.5 · 132 ✖
surface_class 1
- A2_pm_peripheral · 132 ✖
in_cev_map 1
- 1 · 132 ✖
has_activation_state_pdb_pair 1
- 0 132
| id | gene_symbol | protein_name | tier | evidence_priority ▲ | has_structure | surface_class | pdb_count_total | alphafold_mean_pLDDT | has_cryoEM | has_activation_state_pdb_pair | activation_state_pdb_active | activation_state_pdb_inactive | has_known_aptamer | aptamer_count_pubmed | aptamer_pmids | in_cev_map | opentargets_top_disease_name | opentargets_top_disease_score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P29400 | COL4A5 | Collagen alpha-5(IV) chain | Tier 1.5 | 0.794 | 1 | A2_pm_peripheral | 2 | 48.12 | 0 | 0 | 0 | 0 | 1 | X-linked Alport syndrome | 0.8472963899466404 | |||
| Q14315 | FLNC | Filamin-C | Tier 1.5 | 0.791 | 1 | A2_pm_peripheral | 14 | 75.06 | 0 | 0 | 0 | 0 | 1 | hypertrophic cardiomyopathy 26 | 0.8363192336142512 | |||
| O60315 | ZEB2 | Zinc finger E-box-binding homeobox 2 | Tier 1.5 | 0.789 | 1 | A2_pm_peripheral | 1 | 48.16 | 0 | 0 | 1 | 3 | 27719642, 24146916, 18698484 | 1 | Mowat-Wilson syndrome | 0.8313744323041312 | ||
| P31040 | SDHA | Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial | Tier 1.5 | 0.785 | 1 | A2_pm_peripheral | 4 | 93.94 | 1 | 0 | 0 | 0 | 1 | mitochondrial complex II deficiency, nuclear type 1 | 0.815589203208636 | |||
| P11274 | BCR | Breakpoint cluster region protein | Tier 1.5 | 0.785 | 1 | A2_pm_peripheral | 5 | 64.81 | 0 | 0 | 1 | 20 | 41951939, 41535871, 40882628, 37937247, 37103734, 32929022, 32507237, 31825964, 31650445, 31295447, 29299123, 28686804, 25809097, 23836560, 22411871, 21810089, 21653319, 21030439, 16990253, 11713794 | 1 | chronic myelogenous leukemia | 0.8183048540102864 | ||
| O95630 | STAMBP | STAM-binding protein | Tier 1.5 | 0.782 | 1 | A2_pm_peripheral | 5 | 84.0 | 0 | 0 | 0 | 0 | 1 | microcephaly-capillary malformation syndrome | 0.8060251236043802 | |||
| Q12840 | KIF5A | Kinesin heavy chain isoform 5A | Tier 1.5 | 0.781 | 1 | A2_pm_peripheral | 4 | 75.31 | 1 | 0 | 0 | 0 | 1 | hereditary spastic paraplegia 10 | 0.8029405627392309 | |||
| O00330 | PDHX | Pyruvate dehydrogenase protein X component, mitochondrial | Tier 1.5 | 0.779 | 1 | A2_pm_peripheral | 5 | 77.31 | 1 | 0 | 0 | 0 | 1 | pyruvate dehydrogenase E3-binding protein deficiency | 0.7957753555992844 | |||
| Q9NQG7 | HPS4 | BLOC-3 complex member HPS4 | Tier 1.5 | 0.779 | 1 | A2_pm_peripheral | 1 | 61.66 | 1 | 0 | 0 | 0 | 1 | Hermansky-Pudlak syndrome with pulmonary fibrosis | 0.7967575753847002 | |||
| P12814 | ACTN1 | Alpha-actinin-1 | Tier 1.5 | 0.777 | 1 | A2_pm_peripheral | 4 | 85.25 | 0 | 0 | 0 | 0 | 1 | platelet-type bleeding disorder 15 | 0.7887662502912471 | |||
| O00468 | AGRN | Agrin | Tier 1.5 | 0.777 | 1 | A2_pm_peripheral | 1 | 68.81 | 1 | 0 | 0 | 0 | 1 | congenital myasthenic syndrome 8 | 0.7912009864338403 | |||
| Q9ULC3 | RAB23 | Ras-related protein Rab-23 | Tier 1.5 | 0.776 | 1 | A2_pm_peripheral | 6 | 79.56 | 1 | 0 | 1 | 1 | 23618401 | 1 | RAB23-related Carpenter syndrome | 0.7879955689930709 | ||
| P55263 | ADK | Adenosine kinase | Tier 1.5 | 0.769 | 1 | A2_pm_peripheral | 4 | 93.31 | 0 | 0 | 1 | 2 | 26051465 | 1 | adenosine kinase deficiency | 0.7617058236708037 | ||
| Q9NZ09 | UBAP1 | Ubiquitin-associated protein 1 | Tier 1.5 | 0.764 | 1 | A2_pm_peripheral | 3 | 62.5 | 0 | 0 | 0 | 0 | 1 | spastic paraplegia 80, autosomal dominant | 0.7464670113492812 | |||
| Q6NZI2 | CAVIN1 | Caveolae-associated protein 1 | Tier 1.5 | 0.76 | 1 | A2_pm_peripheral | 3 | 67.38 | 0 | 0 | 0 | 0 | 1 | congenital generalized lipodystrophy type 4 | 0.7317728549444928 | |||
| Q92997 | DVL3 | Segment polarity protein dishevelled homolog DVL-3 | Tier 1.5 | 0.759 | 1 | A2_pm_peripheral | 9 | 58.91 | 0 | 0 | 0 | 0 | 1 | autosomal dominant Robinow syndrome | 0.7284158836126389 | |||
| P22735 | TGM1 | Protein-glutamine gamma-glutamyltransferase K | Tier 1.5 | 0.754 | 1 | A2_pm_peripheral | 1 | 84.12 | 0 | 0 | 0 | 0 | 1 | autosomal recessive congenital ichthyosis | 0.714755023666953 | |||
| P31939 | ATIC | Bifunctional purine biosynthesis protein ATIC | Tier 1.5 | 0.754 | 1 | A2_pm_peripheral | 5 | 97.38 | 0 | 0 | 0 | 0 | 1 | AICA-ribosiduria | 0.7137167364484167 | |||
| P35241 | RDX | Radixin | Tier 1.5 | 0.749 | 1 | A2_pm_peripheral | 2 | 86.56 | 0 | 0 | 1 | 2 | 33253235, 30700648 | 1 | hearing loss, autosomal recessive | 0.6973070672344621 | ||
| Q8IXK2 | GALNT12 | Polypeptide N-acetylgalactosaminyltransferase 12 | Tier 1.5 | 0.748 | 1 | A2_pm_peripheral | 1 | 93.5 | 0 | 0 | 0 | 0 | 1 | colorectal cancer, susceptibility to, 1 | 0.6932727729787528 | |||
| O43516 | WIPF1 | WAS/WASL-interacting protein family member 1 | Tier 1.5 | 0.737 | 1 | A2_pm_peripheral | 4 | 58.5 | 0 | 0 | 0 | 0 | 1 | Wiskott-Aldrich syndrome | 0.6561328889736038 | |||
| Q12929 | EPS8 | Epidermal growth factor receptor kinase substrate 8 | Tier 1.5 | 0.731 | 1 | A2_pm_peripheral | 2 | 70.31 | 0 | 0 | 0 | 0 | 1 | autosomal recessive nonsyndromic hearing loss 102 | 0.6354471967036509 | |||
| Q9NZ56 | FMN2 | Formin-2 | Tier 1.5 | 0.729 | 1 | A2_pm_peripheral | 2 | 49.97 | 0 | 0 | 0 | 0 | 1 | autosomal recessive non-syndromic intellectual disability | 0.6298956049368037 | |||
| P32121 | ARRB2 | Beta-arrestin-2 | Tier 1.5 | 0.719 | 1 | A2_pm_peripheral | 1 | 83.81 | 1 | 0 | 1 | 4 | 24736311, 40652239, 29054528 | 1 | cancer | 0.5962458729823639 | ||
| O95425 | SVIL | Supervillin | Tier 1.5 | 0.718 | 1 | A2_pm_peripheral | 2 | 53.44 | 0 | 0 | 0 | 0 | 1 | myofibrillar myopathy 10 | 0.5924877747412329 | |||
| P09769 | FGR | Tyrosine-protein kinase Fgr | Tier 1.5 | 0.716 | 1 | A2_pm_peripheral | 3 | 82.19 | 0 | 0 | 1 | 1 | 39564692 | 1 | chronic myelogenous leukemia | 0.5869168331059803 | ||
| P10398 | ARAF | Serine/threonine-protein kinase A-Raf | Tier 1.5 | 0.709 | 1 | A2_pm_peripheral | 6 | 70.06 | 0 | 0 | 0 | 0 | 1 | cancer | 0.5616780822043126 | |||
| Q01581 | HMGCS1 | Hydroxymethylglutaryl-CoA synthase, cytoplasmic | Tier 1.5 | 0.707 | 1 | A2_pm_peripheral | 1 | 91.31 | 0 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.55518193177393 | |||
| Q9NT62 | ATG3 | Ubiquitin-like-conjugating enzyme ATG3 | Tier 1.5 | 0.707 | 1 | A2_pm_peripheral | 4 | 73.38 | 0 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.5571514462681344 | |||
| Q02156 | PRKCE | Protein kinase C epsilon type | Tier 1.5 | 0.706 | 1 | A2_pm_peripheral | 2 | 79.94 | 0 | 0 | 0 | 0 | 1 | acute myeloid leukemia | 0.5549599198877609 | |||
| P42680 | TEC | Tyrosine-protein kinase Tec | Tier 1.5 | 0.705 | 1 | A2_pm_peripheral | 1 | 85.0 | 0 | 0 | 1 | 13 | 39352470, 39329798, 36414190, 36105684, 35624657, 35462326, 35006795, 30578658, 30398689, 27548775, 26843427, 25016253, 24875764 | 1 | alopecia areata | 0.5491699656070116 | ||
| P17252 | PRKCA | Protein kinase C alpha type | Tier 1.5 | 0.704 | 1 | A2_pm_peripheral | 6 | 86.38 | 0 | 0 | 1 | 1 | 41505229 | 1 | acute myeloid leukemia | 0.547429504944985 | ||
| P00326 | ADH1C | Alcohol dehydrogenase 1C | Tier 1.5 | 0.704 | 1 | A2_pm_peripheral | 2 | 98.12 | 0 | 0 | 0 | 0 | 1 | alcohol drinking | 0.5465864505308649 | |||
| Q99828 | CIB1 | Calcium and integrin-binding protein 1 | Tier 1.5 | 0.701 | 1 | A2_pm_peripheral | 9 | 75.75 | 0 | 0 | 0 | 0 | 1 | epidermodysplasia verruciformis | 0.5381616248572979 | |||
| O15511 | ARPC5 | Actin-related protein 2/3 complex subunit 5 | Tier 1.5 | 0.699 | 1 | A2_pm_peripheral | 2 | 92.19 | 1 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.5305805352966168 | |||
| P30154 | PPP2R1B | Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform | Tier 1.5 | 0.699 | 1 | A2_pm_peripheral | 1 | 92.81 | 1 | 0 | 0 | 0 | 1 | cancer | 0.5305484520119053 | |||
| Q16774 | GUK1 | Guanylate kinase | Tier 1.5 | 0.698 | 1 | A2_pm_peripheral | 14 | 93.94 | 0 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.526507567426656 | |||
| Q96PY5 | FMNL2 | Formin-like protein 2 | Tier 1.5 | 0.695 | 1 | A2_pm_peripheral | 1 | 76.44 | 0 | 0 | 1 | 1 | 41149482 | 1 | open-angle glaucoma | 0.5157968177633478 | ||
| O60861 | GAS7 | Growth arrest-specific protein 7 | Tier 1.5 | 0.694 | 1 | A2_pm_peripheral | 2 | 83.75 | 0 | 0 | 0 | 0 | 1 | open-angle glaucoma | 0.5145811266752988 | |||
| Q53QZ3 | ARHGAP15 | Rho GTPase-activating protein 15 | Tier 1.5 | 0.691 | 1 | A2_pm_peripheral | 1 | 76.06 | 0 | 0 | 0 | 0 | 1 | diverticular disease | 0.5042377909782373 | |||
| O00762 | UBE2C | Ubiquitin-conjugating enzyme E2 C | Tier 1.5 | 0.689 | 1 | A2_pm_peripheral | 9 | 88.56 | 1 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.49682303083942114 | |||
| P09543 | CNP | 2',3'-cyclic-nucleotide 3'-phosphodiesterase | Tier 1.5 | 0.689 | 1 | A2_pm_peripheral | 1 | 87.25 | 0 | 0 | 1 | 9 | 40034273, 38569854, 37704353, 35528922, 31171207, 30089209, 27192549, 19021295 | 1 | myopia 2, autosomal dominant | 0.49606855995054094 | ||
| P31948 | STIP1 | Stress-induced-phosphoprotein 1 | Tier 1.5 | 0.689 | 1 | A2_pm_peripheral | 8 | 89.75 | 1 | 0 | 1 | 7 | 41406518, 38012811, 34831332, 32614006, 27681499, 24654750, 24013070 | 1 | neurodegenerative disease | 0.4967711525222825 | ||
| P21980 | TGM2 | Protein-glutamine gamma-glutamyltransferase 2 | Tier 1.5 | 0.688 | 1 | A2_pm_peripheral | 17 | 92.88 | 1 | 0 | 1 | 1 | 35980938 | 1 | neurodegenerative disease | 0.49455272812698803 | ||
| Q86SR1 | GALNT10 | Polypeptide N-acetylgalactosaminyltransferase 10 | Tier 1.5 | 0.688 | 1 | A2_pm_peripheral | 2 | 90.75 | 0 | 0 | 0 | 0 | 1 | obesity | 0.49376752835968046 | |||
| O75815 | BCAR3 | Breast cancer anti-estrogen resistance protein 3 | Tier 1.5 | 0.687 | 1 | A2_pm_peripheral | 1 | 65.69 | 0 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.4887088231206927 | |||
| Q96FQ6 | S100A16 | Protein S100-A16 | Tier 1.5 | 0.687 | 1 | A2_pm_peripheral | 3 | 81.12 | 0 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.4899214982350221 | |||
| Q8TBX8 | PIP4K2C | Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma | Tier 1.5 | 0.684 | 1 | A2_pm_peripheral | 5 | 80.31 | 0 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.47990990136472794 | |||
| O00194 | RAB27B | Ras-related protein Rab-27B | Tier 1.5 | 0.684 | 1 | A2_pm_peripheral | 1 | 84.56 | 0 | 0 | 0 | 0 | 1 | major depressive disorder | 0.4805047942947544 | |||
| O15247 | CLIC2 | Chloride intracellular channel protein 2 | Tier 1.5 | 0.682 | 1 | A2_pm_peripheral | 3 | 92.94 | 0 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.47298055353356755 |
Advanced export
JSON shape: default, array, newline-delimited
CREATE VIEW v_targets AS
SELECT f.id, n.gene_symbol, n.protein_name, tg.tier,
-- evidence_priority: DETERMINISTIC, reproducible from real DB columns (no LLM).
-- Transparent weights over harvested evidence: structure 0.35, disease importance
-- 0.30 (Open Targets top-disease score), PREDICTED surface accessibility 0.20,
-- EV detection 0.15. A heuristic ranking aid, not a validation; surface/EV terms
-- are predictions/detections, NOT measured EV-surface exposure.
ROUND(
0.35*(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1.0
WHEN CAST(COALESCE(NULLIF(f.alphafold_mean_pLDDT,''),'0') AS REAL)>0 THEN 0.3 ELSE 0.0 END)
+ 0.30*MIN(CAST(COALESCE(NULLIF(f.opentargets_top_disease_score,''),'0') AS REAL), 1.0)
+ 0.20*(CASE sc.surface_class WHEN 'A_surface' THEN 1.0 WHEN 'A_assoc' THEN 0.5 WHEN 'A2_pm_peripheral' THEN 0.2 ELSE 0.0 END)
+ 0.15*(CASE WHEN CAST(COALESCE(f.in_cev_map,0) AS INTEGER)=1 THEN 1.0 ELSE 0.0 END)
, 3) AS evidence_priority,
(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1 ELSE 0 END) AS has_structure,
sc.surface_class,
f.pdb_count_total, f.alphafold_mean_pLDDT, f.has_cryoEM,
f.has_activation_state_pdb_pair, f.activation_state_pdb_active, f.activation_state_pdb_inactive,
f.has_known_aptamer, f.aptamer_count_pubmed, ap.aptamer_pmids,
f.in_cev_map, f.opentargets_top_disease_name, f.opentargets_top_disease_score
FROM v_target_full f
LEFT JOIN target_names n ON n.target_id=f.id
LEFT JOIN targets tg ON tg.id=f.id
LEFT JOIN target_aptamer_pmids ap ON ap.target_id=f.id
LEFT JOIN membrane_surface_class sc ON sc.target_id=f.id;